[Antifungal prophylaxis in HIV-seropositive liver transplant recipients].
Seropositive human immunodeficiency virus (HIV) patients have a high prevalence of chronic liver disease for which liver transplantation is the only possible treatment. Risk of fungal infection in this population may be very high. We describe the clinical course of the early postoperative period in a patient coinfected with HIV and hepatitis C virus undergoing liver transplantation. We discuss antifungal prophylaxis indications and drugs of choice in relation to their efficacy and safety profile. Other medical treatments are described, as well as possible pharmacokinetic interactions. Antifungal prophylaxis with anidulafungin has proven effective and has presented no significant adverse effects on a patient at high risk of fungal infection and multiple risk factors for drug interactions.